WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012051213) THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/051213    International Application No.:    PCT/US2011/055839
Publication Date: 19.04.2012 International Filing Date: 11.10.2011
IPC:
C07D 471/14 (2006.01), C07D 401/04 (2006.01), A61K 31/437 (2006.01), A61P 25/00 (2006.01)
Applicants: DART NEUROSCIENCE (CAYMAN) LTD; 4th Floor, Queensgate House, 113 South Church Street P.O. Box 1994 Grand Cayman KY1-1104 (KY) (For All Designated States Except US).
GUPTA, Varsha [US/US]; (US) (For US Only).
RENICK, Joel [US/US]; (US) (For US Only).
FREESTONE, Graeme [GB/US]; (US) (For US Only).
KAPLAN, Alan, P. [US/US]; (US) (For US Only)
Inventors: GUPTA, Varsha; (US).
RENICK, Joel; (US).
FREESTONE, Graeme; (US).
KAPLAN, Alan, P.; (US)
Agent: MALLON, Joseph, J.; Knobbe Martens Olson & Bear LLP 2040 Main Street 14th Floor Irvine, CA 92614 (US)
Priority Data:
61/393,327 14.10.2010 US
Title (EN) THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS
(FR) ANALOGUES 5,6,5-TRICYCLIQUES THÉRAPEUTIQUES
Abstract: front page image
(EN)The invention provides a novel chemical series of formula (I), as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and negatively modulating the α5 subtype of GABAA, and use of the compound of formula (I) in the manufacture of a medicament for the treatment of GABAA receptor associated disorders. The invention further provides a method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).
(FR)L'invention concerne une nouvelle série chimique de formule (I), ainsi que des procédés pour l'utiliser pour la liaison au site benzodiazépine du récepteur GABAA et la modulation négative du sous-type α5 de GABAA, et l'utilisation du composé de formule (I) dans la fabrication d'un médicament destiné au traitement de troubles associés au récepteur GABAA. L'invention concerne en outre un procédé de modulation d'un ou plusieurs sous-types de GABAA chez un animal, comprenant l'administration à l'animal d'une quantité efficace d'un composé de formule (I).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)